DelveInsight’s ‘Allergic Rhinitis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Allergic Rhinitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Allergic Rhinitis pipeline domain.
For Vasculitis emerging drugs, the Vasculitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Allergic Rhinitis Pipeline Report
- DelveInsight’s Allergic Rhinitis Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Allergic Rhinitis treatment.
- The leading Allergic Rhinitis companies include Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals Inc., Revolo Biotherapeutics, Emergo Therapeutics, Advagene Biopharma, AOBiome LLC, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, Worg Pharmaceuticals, ABVC Biopharma, Revelation Biosciences, Altamira Therapeutics, Qyuns Therapeutics, Dobecure, Funpep, GL Pharm Tech, Archivel Farma, Nasus Pharma, RIKEN, Paradigm Pharmaceuticals, DC4U, United Biomedical, Marinomed Biotech, Desentum, Roxall Medizin, and others are evaluating their lead assets to improve the Allergic Rhinitis treatment landscape.
- Key Allergic Rhinitis pipeline therapies in various stages of development include AI-201901, Injectable MPL allergy vaccine, REGN5713-5714-5715, House dust mite allergy immunotherapy, Birch pollen allergy vaccine tablet, B 244, AD 17002, CSPCHA-115, MM09-MG01, MG 01/T 517, IRL 201104, REVTx-99b, QX 005N, FPP004, GLF1MO, INI2004, RUTI, FMXIN002, UB-211, and others.
- In May 2022, ABVC Biopharma announced that BioKey, a wholly-owned subsidiary of the company based in Fremont, California, entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd. to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under US FDA IND regulatory requirements. CEN501 is a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients.
- In March 2022, Altamira Therapeutics announced the completion of patient enrollment in its Bentrio trial in house dust mite (“HDM”) allergic rhinitis. The Company expects to release top-line results from the trial during the second quarter of 2022.
- In January 2022, Glenmark announced the approval of Ryaltris. Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older. Glenmark, in January 2022, entered into licensing agreement with Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong, and Vietnam.
Request a sample and discover the recent breakthroughs happening in the Allergic Rhinitis pipeline landscape @ Allergic Rhinitis Pipeline Outlook
Allergic Rhinitis Overview
Allergic rhinitis occurs when the body’s immune system overreacts to something in the environment (triggers). Allergens, which are normally harmless compounds that cause allergic reactions in some people, are to blame. When Allergic Rhinitis symptoms appear in late summer or early fall, some people refer to it as hay fever. Dust mites, mold, pet dander, and pollen from trees and plants are all common Allergic Rhinitis causes. Allergic Rhinitis symptoms include sneezing, nasal congestion, and nose, throat, mouth, and eyes irritation.
An Allergic Rhinitis diagnosis is made based on a complete history, which is confirmed by examination findings (physical examination and, if necessary, nasal endoscopy) and, if necessary, allergen-specific IgE testing. Other tests for Allergic Rhinitis diagnosis may be required, such as a nasal allergen challenge, CT scans, evaluation of nasal nitric oxide and ciliary beat frequency, nasal smears, nasal cultures, and -transferrin analysis of nasal fluid.
Avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays, leukotriene receptor antagonists (LTRAs), and allergen immunotherapy are the main Allergic Rhinitis treatment options.
Find out more about Allergic Rhinitis medication @ Best Antihistamine for Allergic Rhinitis
Vasculitis Pipeline Analysis: Drug Profile
REGN5713-5714-5715: Regeneron Pharmaceuticals
REGN5713-5714-5715 is a three-part cocktail of Bet v1 monoclonal antibodies. REGN5713-5714-5715 is being studied as intravenous injections in Phase III clinical trials for the treatment of allergic rhinitis and conjunctivitis by Regeneron Pharmaceuticals.
MM09-MG01: Immunotek
Inmunotek is developing M 601, a subcutaneously administered immunotherapy product containing biological extracts of house dust mites (MM09-MG01). A Phase III prospective, randomized, placebo-controlled, multicenter study of three active treatment groups versus one placebo group has begun to determine the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and D. farinae) and grass pollen.
Vasculitis Pipeline Therapies and Key Companies
- MM09-MG01: Immunotek
- REGN5713-5714-5715: Regeneron Pharmaceuticals
- AI-201901: Abdi Ibrahim Pharmaceuticals
- MPL allergy vaccine: Allergy Therapeutics
- IRL 201104: Revolo Biotherapeutics
- PA9159: Anhui Palo Alto Pharmaceuticals
- AD 17002: Advagene Biopharma
Learn more about the novel and emerging Allergic Rhinitis pipeline therapies @ Allergic Rhinitis Clinical Trials
Allergic Rhinitis Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Subcutaneous
- Topical
- Intravitreal
- By Molecule Type
- Gene therapy
- Small molecule
- Polymers
- Peptides
- Monoclonal antibodies
Scope of the Allergic Rhinitis Pipeline Report
-
- Coverage: Global
- Key Allergic Rhinitis Companies: Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals (NASDAQ: REGN), Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S (CPH: HLUN-A), CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, Revelation Biosciences (NASDAQ: REVB), and others.
- Key Allergic Rhinitis Pipeline Therapies: AI-201901, Injectable MPL allergy vaccine, REGN5713-5714-5715, House dust mite allergy immunotherapy, Birch pollen allergy vaccine tablet, B 244, AD 17002, CSPCHA-115, MM09-MG01, MG 01/T 517, REVTx-99b, and others.
Dive deep into rich insights for drugs used for Allergic Rhinitis treatment; visit @ Allergic Rhinitis Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Allergic Rhinitis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Allergic Rhinitis Pipeline Therapeutics |
| 6. | Allergic Rhinitis Pipeline: Late Stage Products (Phase III) |
| 7. | Allergic Rhinitis Pipeline: Late Stage Products (Phase III) |
| 8. | Allergic Rhinitis Pipeline: Mid Stage Products (Phase II) |
| 9. | Allergic Rhinitis Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Allergic Rhinitis therapy in the pipeline, reach out @ Allergic Rhinitis Medication
Related Reports
Allergic Rhinitis Epidemiology Forecast
Allergic Rhinitis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Allergic Rhinitis epidemiology in the 7MM.
Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Allergic Rhinitis companies such as Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., among others.
Perennial Allergic Rhinitis Pipeline
Perennial Allergic Rhinitis Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Perennial Allergic Rhinitis companies such as ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, among others.
Seasonal Allergic Rhinitis Pipeline
Seasonal Allergic Rhinitis Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Seasonal Allergic Rhinitis companies such as Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, among others.
Perennial Allergic Rhinitis Market
Perennial Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Perennial Allergic Rhinitis companies such as ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, among others.
Seasonal Allergic Rhinitis Market
Seasonal Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Seasonal Allergic Rhinitis companies such as Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, among others.
Other Trending Reports
Goitre Market | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
Allergic Disease Market Landscape
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187